Fenethylline

Identification

Name
Fenethylline
Accession Number
DB01482
Description
Not Available
Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 341.415
Monoisotopic: 341.185175001
Chemical Formula
C18H23N5O2
Synonyms
  • Amfetyline
  • Fenethylline
  • Fenetilina
  • Fenetillina
  • Fenetylline
  • Fenetyllinum
External IDs
  • D323
  • HOMBURG-814

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Fenethylline can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Fenethylline can be increased when combined with Abatacept.
AbirateroneThe serum concentration of Fenethylline can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Fenethylline.
AcenocoumarolThe metabolism of Fenethylline can be decreased when combined with Acenocoumarol.
AcetaminophenThe metabolism of Fenethylline can be decreased when combined with Acetaminophen.
AcetazolamideAcetazolamide may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.
AcyclovirThe metabolism of Fenethylline can be decreased when combined with Acyclovir.
AdalimumabThe serum concentration of Fenethylline can be decreased when it is combined with Adalimumab.
AdenosineThe therapeutic efficacy of Adenosine can be decreased when used in combination with Fenethylline.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Fenethylline hydrochlorideYA7K8ADZ2V1892-80-4MVXGSLGVWBVZCA-UHFFFAOYSA-N
International/Other Brands
Captagon (Meda)

Categories

ATC Codes
N06BA10 — Fenetylline
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
YZ0N7VL5R3
CAS number
3736-08-1
InChI Key
NMCHYWGKBADVMK-UHFFFAOYSA-N
InChI
InChI=1S/C18H23N5O2/c1-13(11-14-7-5-4-6-8-14)19-9-10-23-12-20-16-15(23)17(24)22(3)18(25)21(16)2/h4-8,12-13,19H,9-11H2,1-3H3
IUPAC Name
1,3-dimethyl-7-{2-[(1-phenylpropan-2-yl)amino]ethyl}-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
CC(CC1=CC=CC=C1)NCCN1C=NC2=C1C(=O)N(C)C(=O)N2C

References

Synthesis Reference

Kohlstaedt, E. and Klingler, K.H.; U.S. Patent 3,029,239; April 10, 1962; assigned to Chemiewerke Homburg.

General References
Not Available
PubChem Compound
102710
PubChem Substance
46505193
ChemSpider
18398
RxNav
24840
ChEBI
135451
ChEMBL
CHEMBL2111152
Wikipedia
Fenethylline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)227-229Kohlstaedt, E. and Klingler, K.H.; U.S. Patent 3,029,239; April 10, 1962; assigned to Chemiewerke Homburg.
Predicted Properties
PropertyValueSource
logP1.52ChemAxon
pKa (Strongest Basic)10.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area70.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity96.34 m3·mol-1ChemAxon
Polarizability36.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9145
Caco-2 permeable-0.6141
P-glycoprotein substrateSubstrate0.7324
P-glycoprotein inhibitor INon-inhibitor0.706
P-glycoprotein inhibitor IIInhibitor0.7238
Renal organic cation transporterNon-inhibitor0.6446
CYP450 2C9 substrateNon-substrate0.722
CYP450 2D6 substrateNon-substrate0.8058
CYP450 3A4 substrateSubstrate0.6524
CYP450 1A2 substrateNon-inhibitor0.7432
CYP450 2C9 inhibitorNon-inhibitor0.7196
CYP450 2D6 inhibitorNon-inhibitor0.7984
CYP450 2C19 inhibitorNon-inhibitor0.6107
CYP450 3A4 inhibitorInhibitor0.6417
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.624
Ames testNon AMES toxic0.5
CarcinogenicityNon-carcinogens0.788
BiodegradationNot ready biodegradable0.9918
Rat acute toxicity3.1898 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.6707
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Curator comments
This enzyme listing is based on pharmacokinetic data for methylxanthines as a drug class. Methylxanthines are metabolized by CYP1A2. This drug is a methylxanthine and is therefore assumed to be metabolized by this enzyme.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ: Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics. 1996 Aug;6(4):291-6. [PubMed:8873215]
  2. Hakooz NM: Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. Curr Drug Metab. 2009 May;10(4):329-38. [PubMed:19519341]
  3. Rasmussen BB, Brosen K: Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996 Jun;18(3):254-62. [PubMed:8738764]
  4. Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB: PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95. doi: 10.1097/FPC.0b013e3283505d5e. [PubMed:22293536]
  5. Theophylline metabolic pathway [Link]
  6. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine [File]

Drug created on July 31, 2007 07:09 / Updated on June 12, 2020 10:51

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates